Figure 1 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer

Read full text Summarise with VIRAT
Authors: Charlie Chung, Brian Yueh, Santhilal Subhash, Onur Eskiocak, Aaron Nizam, Marissa G. Viola, Pascal Belleau, Ariel Kredentser, Arisa Kapedani, Alexander Krasnitz, Ken Simon, Werner Meier
+3 more Marina Frimer, Gary L. Goldberg, Semir Beyaz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The antigen presentation and processing are downregulated in HGEC organoids. A, RNA-based ancestry estimation of endometrial cancer (EC) PDOs used in the experiments (n = 50). B, RNA-based ancestry estimation of EC PDOs used in the experiments classified based on the tumor grade. C, Bar plot showing endometrial cancer patients’ microsatellite stability status (n = 50) and associated BMI (cancer; n = 50, benign; n = 8). MSI, microsatellite instability; MSS, microsatellite stability. D, Heatmap generated from RNA-seq data using paired EC PDO lines (low-grade; n = 4, high-grade; n = 7, normal; n = 11). E, Violin plots highlighting MHC-II genes from (D) in HGEC (top, red) and LGEC (bottom, blue) PDOs and their matched normal pairs. F, Steady-state MHC-I, -II genes and PD-L1 mRNA expression levels among matched normal and HGEC PDOs analyzed by RT-PCR (n = 10 for each). Each dot represents a relative mRNA quantity of a target gene normalized to a reference gene, HSP90A from individual PDO line. G, Mean fluorescent intensity (MFI) of immunomodulatory protein expression levels of EC PDOs at steady-state measured by flow cytometry. (normal; n = 7, high-grade; n = 9). Ordinary one-way ANOVA (F and G) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Endometrial and Cervical Cancer Treatments

Publication details

Publication date
25 March 2026
Language
EN